reference/10702748

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10702748

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Multicenter Study
endingPage	e16
issn	0390-6078 1592-8721
issueIdentifier	2
pageRange	e14-e16
publicationName	Haematologica
startingPage	e14
bibliographicCitation	Gambella M, Rocci A, Passera R, Gay F, Omede P, Crippa C, Corradini P, Romano A, Rossi D, Ladetto M, Boccadoro M, Palumbo A. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica. 2014 Feb 01;99(2):e14–6. doi: 10.3324/haematol.2013.090142.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_57237e0f91ec178c4bcc15644b481a52 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_603915034f9a74a041826e604e1cf2eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_149f3386ae90653b16251372d8fe0d1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bfd309901a080f1c9b8d42fcbcb95d7d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa6e30bae357ead342003232004c02f5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ae657157ea3e685d7db556d3d0bce943 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7c502a9f2c14f23693a6c030d5d53242 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a9e168f478a3701b99e07d62f8a8163 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27a5260f0a45b1838ff6e037f667c73b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_722e271c737fddfbbc8c01e44b639d3a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8043eaafa0286d68bb9523875bd2c6c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_761f6f6cd7aabd1a9911bbf7b96ad1b9
date	2014-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC3912976 https://pubmed.ncbi.nlm.nih.gov/24497562 https://doi.org/10.3324/haematol.2013.090142
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3942 https://portal.issn.org/resource/ISSN/1592-8721 https://portal.issn.org/resource/ISSN/0390-6078
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib
discusses	http://id.nlm.nih.gov/mesh/M0157985 http://id.nlm.nih.gov/mesh/M0469399 http://id.nlm.nih.gov/mesh/M000615358 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0350110 http://id.nlm.nih.gov/mesh/M0014578 http://id.nlm.nih.gov/mesh/M0006678 http://id.nlm.nih.gov/mesh/M0022149 http://id.nlm.nih.gov/mesh/M0002834 http://id.nlm.nih.gov/mesh/M0018225 http://id.nlm.nih.gov/mesh/M0021788
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D004268Q000096 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D014157Q000096 http://id.nlm.nih.gov/mesh/D009363Q000096 http://id.nlm.nih.gov/mesh/D009101Q000401 http://id.nlm.nih.gov/mesh/D001897Q000008 http://id.nlm.nih.gov/mesh/D014408Q000096 http://id.nlm.nih.gov/mesh/D015972Q000187 http://id.nlm.nih.gov/mesh/D009101Q000188 http://id.nlm.nih.gov/mesh/D011719Q000008 http://id.nlm.nih.gov/mesh/D009101Q000378
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000069286 http://id.nlm.nih.gov/mesh/D000071701 http://id.nlm.nih.gov/mesh/D000071717
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_77517a4ebde4224a7c9dbd3c0434d4e4 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID387447 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7494

Total number of triples: 67.